Revenue growth accelerated to 21.2% in 2026Q1, while operating income improved to $22.4 million as the company began to capture scale efficiencies despite COGS consuming 69.6% of revenue.
| Sales/Revenue | 1.49B | 1.42B | 1.25B | 1.06B | 859.54M | 667.51M | 377.22M | 212.52M |
| Revenue Growth % | 16.46% | 13.85% | 18.5% | 22.82% | 28.77% | 76.96% | 77.5% | - |
| Cost of Goods Sold | 1.05B | 1.02B | 848.57M | 753.57M | 622.52M | 466M | 242.9M | 150.12M |
| COGS % of Revenue | - | 71.47% | 67.83% | 71.38% | 72.43% | 69.81% | 64.39% | 70.64% |
| Gross Profit | 446.48M | 406.35M | 402.4M | 302.1M | 237.02M | 201.51M | 134.32M | 62.4M |
| Gross Margin % | 29.87% | 28.53% | 32.17% | 28.62% | 27.57% | 30.19% | 35.61% | 29.36% |
| Gross Profit Growth % | - | 0.98% | 33.2% | 27.46% | 17.62% | 50.02% | 115.27% | - |
| Operating Expenses | 401.2M | 380.64M | 434.01M | 491.23M | 447.19M | 487.86M | 118.88M | 47.16M |
| OpEx % of Revenue | - | 26.72% | 34.69% | 46.53% | 52.03% | 73.09% | 31.52% | 22.19% |
| Selling, General & Admin | 388.1M | 382.2M | 363.06M | 410.79M | 377.99M | 433.73M | 87.84M | 41.06M |
| SG&A % of Revenue | - | 26.83% | 29.02% | 38.91% | 43.98% | 64.98% | 23.29% | 19.32% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 914K | 0 | 70.95M | 80.44M | 69.2M | 54.14M | 31.05M | 6.09M |
| Operating Income | 45.28M | 25.71M | -31.61M | -189.13M | -210.17M | -286.35M | 15.44M | 15.24M |
| Operating Margin % | 3.03% | 1.8% | -2.53% | -17.92% | -24.45% | -42.9% | 4.09% | 7.17% |
| Operating Income Growth % | - | 181.31% | 83.29% | 10.01% | 26.6% | -1955.1% | 1.28% | - |
| EBITDA | 99.59M | 80.46M | 39.34M | -108.7M | -140.98M | -232.22M | 46.48M | 21.34M |
| EBITDA Margin % | 6.66% | 5.65% | 3.14% | -10.3% | -16.4% | -34.79% | 12.32% | 10.04% |
| EBITDA Growth % | 103.65% | 104.54% | 136.19% | 22.9% | 39.29% | -599.6% | 117.85% | - |
| D&A (Non-Cash Add-back) | 54.31M | 54.75M | 70.95M | 80.44M | 69.2M | 54.14M | 31.05M | 6.09M |
| EBIT | 44.79M | 24.02M | -31.08M | -185.36M | -212.8M | -294.19M | -22.28M | 15.24M |
| Net Interest Income | -6.8M | -11.66M | -26.54M | -21.22M | -19.93M | -38.91M | 0 | -5.41M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 22.13M | 0 |
| Interest Expense | 6.8M | 11.66M | 26.54M | 21.22M | 19.93M | 38.91M | 22.13M | 5.41M |
| Other Income/Expense | -11.69M | -13.34M | -26M | -17.45M | -22.56M | -46.75M | -59.85M | -7.37M |
| Pretax Income | 33.59M | 12.36M | -57.61M | -206.58M | -232.73M | -333.11M | -44.41M | 7.88M |
| Pretax Margin % | 2.25% | 0.87% | -4.61% | -19.57% | -27.08% | -49.9% | -11.77% | 3.71% |
| Income Tax | 10.4M | 2.7M | -170K | -20.32M | -17.17M | -25.91M | -6.34M | 2.21M |
| Effective Tax Rate % | 30.95% | 21.84% | 0.3% | 9.84% | 7.38% | 7.78% | 14.28% | 28.01% |
| Net Income | 23.2M | 9.66M | -57.44M | -186.26M | -215.56M | -307.2M | -38.07M | 5.67M |
| Net Margin % | 1.55% | 0.68% | -4.59% | -17.64% | -25.08% | -46.02% | -10.09% | 2.67% |
| Net Income Growth % | 165.09% | 116.82% | 69.16% | 13.59% | 29.83% | -706.93% | -771.55% | - |
| Net Income (Continuing) | 23.2M | 9.66M | -57.44M | -186.26M | -215.56M | -307.2M | -38.07M | 5.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.06 | 0.02 | -0.15 | -0.51 | -0.61 | -1.05 | -0.83 | 0.02 |
| EPS Growth % | 157.78% | 113.33% | 70.59% | 16.39% | 41.9% | -26.51% | -5560.53% | - |
| EPS (Basic) | - | 0.03 | -0.15 | -0.51 | -0.61 | -1.05 | -0.83 | 0.02 |
| Diluted Shares Outstanding | 395.08M | 391.14M | 379.15M | 367.46M | 355.28M | 327.52M | 373.65M | 373.65M |
| Basic Shares Outstanding | 387.26M | 386.02M | 379.15M | 367.46M | 355.28M | 327.52M | 373.65M | 373.65M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Clinician wage inflation pressure
According to recent quarterly filings, LifeStance Health Group achieved a 21.2% year-over-year revenue growth rate in 2026Q1, signaling an acceleration from the 17.4% observed in the prior quarter and suggesting that the company's hybrid outpatient model continues to capture significant market share in the behavioral health sector.
The recent uptick in top-line expansion suggests that the company's strategy of scaling its national footprint is successfully driving patient volume. Investors should monitor whether this growth is primarily volume-driven or if recent payor contract negotiations have contributed to higher revenue per visit, as the latter would indicate stronger pricing power.
As reported in financial statements, LifeStance's operating income reached $22.4 million in 2026Q1, a notable improvement from the $18.4 million reported in 2025Q4, indicating that the company is finally beginning to realize the benefits of scale as corporate overhead costs grow slower than gross profit.
The transition from negative operating margins in early 2024 to a 5.5% margin in 2026Q1 suggests that the company is successfully managing its administrative burden. This trend warrants further investigation to determine if this efficiency is sustainable or if it relies on temporary reductions in recruitment-related SG&A spending.
Based on LifeStance's reported figures, the company's net income of $14.2 million in 2026Q1 appears to be bolstered by a significant reduction in stock-based compensation, which dropped to zero in the most recent quarter compared to $16.7 million in the final quarter of 2025.
The volatility in stock-based compensation suggests that reported net income may be subject to significant non-cash fluctuations that obscure underlying operational performance. Analysts should be cautious in extrapolating current profitability levels without accounting for the potential return of equity-based incentives required to retain clinical talent.
Data from the latest income statement reveals that COGS remains the primary expense, consuming approximately 69.6% of revenue in 2026Q1, which highlights the structural difficulty of maintaining profitability in a labor-intensive model where clinician compensation is the dominant variable cost component.
The persistent pressure from clinician wages suggests that LifeStance operates with limited flexibility to absorb inflationary shocks. Unless the company can significantly improve clinician utilization rates, the current cost structure may continue to act as a ceiling on potential margin expansion.
Quick answers to the most common questions about buying LFST stock.
For fiscal year 2025, LifeStance Health Group, Inc. (LFST) reported total revenue of $1.42B. This represents a 570.2% increase compared to $212.5M in 2019.
LifeStance Health Group, Inc. (LFST) is profitable, generating $9.7M in net income for the fiscal year ending 2025 with a net profit margin of 0.7%.
LifeStance Health Group, Inc. (LFST) reported an operating income of $25.7M, resulting in an operating profit margin of 1.8%. This margin reflects the operational efficiency of the business before interest and taxes.
LifeStance Health Group, Inc. (LFST) generated $406.3M in gross profit for the year, representing a gross profit margin of 28.5%. This demonstrates the company's core pricing power and production efficiency.